Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder.

ABSTRACT: BACKGROUND:One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment non-response through effects on neurotransmitter systems relevant to antidepressant efficacy. In post-hoc analyses, increased concentrations of inflammatory markers prior to treatment predict poor antidepressant response. However, limited data exists on whether depressed patients with multiple failed treatment trials in their current episode of depression exhibit increased inflammation. METHODS:Plasma concentrations of inflammatory markers were measured in unmedicated, medically stable patients with MDD (n?=?98) and varying numbers of adequate antidepressant treatment trials in the current depressive episode as measured by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire. Covariates including age, sex, race, education, body mass index (BMI) and severity of depression were included in statistical models where indicated. RESULTS:A significant relationship was found between number of failed treatment trials and tumor necrosis factor (TNF), soluble TNF receptor 2 (sTNF-R2) and interleukin (IL)-6 (all p?

SUBMITTER: Haroon E 

PROVIDER: S-EPMC6427066 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature